J&J Releases 2018 Health for Humanity Report
Johnson & Johnson has released its 2018 Health for Humanity Report, detailing the company’s progress in its environmental, social and governance (ESG) focus areas: advancing better health for all, investing in people, maintaining responsible business practices, and safeguarding the environment. The annual update also includes progress made toward the Company’s Health for Humanity 2020 Goals and commitments to support United Nations Sustainable Development Goals.
The report notes
- Janssen Vaccines & Prevention collaborated with the UK government to open the UK’s first-ever dedicated Vaccine Manufacturing and Innovation Centre targeting pandemics such as Influenza, Ebola, Zika and Malaria.
- The National Health Service (NHS) Innovation and Technology Payment program fast tracked four healthcare innovations including Johnson & Johnson’s Ethicon Plus Sutures recognized for reducing the risk of hospital infections such as the methicillin-resistant staphylococcus aureus (MRSA) “super bug.”
- J&J initiated first ever large-scale efficacy study for an investigational mosaic HIV-1 preventive vaccine being conducted in five southern African countries together with the National Institutes of Health, the HIV Vaccine Trials Network, the Bill & Melinda Gates Foundation, the South African Medical Research Council, and many other partners.
- The company announced a comprehensive partnership with the Rwanda Ministry of Health designed to strengthen and expand access to quality mental healthcare in the country.
- It 104,479 health workers in essential skills-building and leadership development across 67 countries with the goal to deliver better quality of care.
- It expanded partnership with UNICEF with a $10 million pledge to support the crucial work of frontline health workers in delivering care to newborns, children and mothers around the world.
- Co-lead development of connect4children (c4c), a project to create a pan-European clinical trial network by 2024 to facilitate the conduct of pediatric clinical trials in the EU.
- Advanced to “Trendsetter” status on the Center for Political Accountability’s CPA-Zicklin Index, which benchmarks the political disclosure and accountability policies and practices for election-related spending by U.S. public companies.
The report is available to view at http://healthforhumanityreport.jnj.com/
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports
May 13th 2025Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
